FDA warning letters matched to listings
1 FDA warning letter matches 1 listing in this index by exact firm name and the city and state in the letter’s address. The letters were found with FDA’s full-text warning letter search for 12 terms on Nov 8, 2026, which returned 435 letters.
Search terms: med spa, medspa, medical spa, aesthetics, IV therapy, IV hydration, hydration, drip, wellness, hyperbaric, semaglutide, tirzepatide. 1 letters had a matching firm name but a different city or state and were not attached. A letter to a firm with a different legal name, or one that uses none of these terms, would not be found, so a listing without a letter here has not been cleared by FDA.
- Glow Medispa, LLC, Cincinnati, OH. FDA warning letter to Glow Medispa, LLC dba Mint Med, issued Jun 8, 2026 by Center for Drug Evaluation and Research (CDER). Subject as FDA lists it: False & Misleading Claims/Misbranded (Telehealth). Matched by exact firm name, including its legal ending, and the city and state in the letter’s address. A warning letter is the agency’s view when issued, not a court finding. FDA’s warning letter index listed no response or close-out letter for it as of Nov 5, 2026; no later status found as of that date. Letter on fda.gov.
What is an FDA warning letter?
A warning letter is FDA’s notice that it found what it considers significant violations, often in a firm’s marketing or products. It asks the firm to respond and correct them. It is not a court finding or a penalty, and FDA posts close-out letters when it decides the issues were addressed. Each letter above shows the response and close-out letter columns of FDA’s warning letter index as of the date read.
Records are shown as FDA published them, matched by exact firm name, including its legal ending, and city. A warning letter is the agency’s view when issued, not a court finding. Updated Nov 8, 2026. Report an error or add a company response.